Tuesday, March 02, 2010
AstraZeneca lays off 550 workers in Wilmington | 6abc.com
AZ is ending discovery research in thrombosis, acid reflux, ovarian and bladder cancers, systemic scleroderma, schizophrenia, bipolar disorder, depression and anxiety, hepatitis C and vaccines other than respiratory syncytial virus and influenza.
Early-stage discovery research will cease at the group's U.S. facility in Wilmington, Del., while in Sweden, its Lund facility will close.
In the U.K., Charnwood and a smaller facility, acquired with Kudos, in Cambridge, will close. Pharmaceutical development work at the Avon facility will also end, and the group said it aims to sell its Arrow Therapeutics business in London.
Subscribe to:
Post Comments (Atom)
1 comment:
Is AZ finally concentrating on something other than exploiting disease for obscene profits?
Post a Comment